We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen Starts Phase III Enrollment for Heart Failure Drug
Read MoreHide Full Article
Amgen (AMGN - Free Report) , Cytokinetics, Inc. (CYTK - Free Report) and Servier announced that the enrollment for the second phase III study of omecamtiv mecarbil, a novel cardiac myosin activator, has been initiated. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).
The phase III study, METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure) will evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF. The study is being conducted by Cytokinetics in collaboration with Amgen, with funding and strategic support from Servier.
Shares of Amgen have dropped 4.9% compared with the industry’s decline of 14.5%.
Amgen has several interesting candidates in its pipeline, which represents a significant commercial potential. The company is focusing on therapeutic areas like oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Important pipeline candidates include Evenity/romosozumab being evaluated for the treatment of osteoporosis in postmenopausal women at increased risk for fracture and is under review in EU and United States; CNP520 is a BACE inhibitor for Alzheimer's disease and is in phase III study; and tezepelumab being developed for the treatment of severe asthma and is in phase III. Tezepelumab is also in a phase IIa study, being developed for atopic dermatitis.
Celgene’s earnings per share estimates have increased from $10.21 to $10.69 for 2019 and from $11.63 to $12.62 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.
BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 22 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 8.57%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Amgen Starts Phase III Enrollment for Heart Failure Drug
Amgen (AMGN - Free Report) , Cytokinetics, Inc. (CYTK - Free Report) and Servier announced that the enrollment for the second phase III study of omecamtiv mecarbil, a novel cardiac myosin activator, has been initiated. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).
The phase III study, METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure) will evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF. The study is being conducted by Cytokinetics in collaboration with Amgen, with funding and strategic support from Servier.
Shares of Amgen have dropped 4.9% compared with the industry’s decline of 14.5%.
Amgen has several interesting candidates in its pipeline, which represents a significant commercial potential. The company is focusing on therapeutic areas like oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Important pipeline candidates include Evenity/romosozumab being evaluated for the treatment of osteoporosis in postmenopausal women at increased risk for fracture and is under review in EU and United States; CNP520 is a BACE inhibitor for Alzheimer's disease and is in phase III study; and tezepelumab being developed for the treatment of severe asthma and is in phase III. Tezepelumab is also in a phase IIa study, being developed for atopic dermatitis.
Amgen Inc. Price
Amgen Inc. Price | Amgen Inc. Quote
Zacks Rank and Stocks to Consider
Amgen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are Celgene Corp. and BioDelivery Sciences International, Inc. . Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Celgene’s earnings per share estimates have increased from $10.21 to $10.69 for 2019 and from $11.63 to $12.62 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.
BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 22 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 8.57%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>